205 patients were enrolled in a study.The aim of the study was to compare the biodegradable-polymer des with durable polymer des when it comes to reducing the incidence of non-st elevation acute coronary syndrome (nsteacs) associated with adverse events.A selection of patients received resolute integrity rx drug eluting stents as part of the study.Patients were noted to have coronary lesions narrowed by 60%.Adverse events / procedural complications reported included acute in-stent thrombosis, arrhythmia, no-reflow phenomenon and coronary dissection.Revascularization (tlr), mi, lv dysfunction and mortality were reported in hospital.A selection of patients that received durable-polymer des (including resolute integrity) consented to have repeat coronary angiography within 1 year.Angina pains were reported with a small number of patients requiring tlr and experiencing mi.
|